



## Test Definition: NMEM

Red Blood Cell Membrane Disorders Gene Panel, Next-Generation Sequencing, Varies

---

### Overview

#### Useful For

Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of a red blood cell (RBC) membrane disorder

Second-tier testing for patients in whom previous targeted gene variant analyses were negative for a specific RBC membrane disorder

Establishing a diagnosis of a hereditary RBC membrane disorder, allowing for appropriate management and surveillance of disease features based on the gene involved, especially if splenectomy is a consideration(5)

Identifying variants within genes associated with phenotypic severity, allowing for predictive testing and further genetic counseling

#### Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 12 genes associated with red blood cell (RBC) membrane disorders including hereditary spherocytosis, hereditary elliptocytosis, hereditary pyropoikilocytosis, Southeast Asian ovalocytosis, hereditary stomatocytosis (both overhydrated and dehydrated/hereditary xerocytosis subtypes), and cryohydrocytosis(1-3): *ABCB6*, *ANK1*, *EPB41*, *EPB42*, *GYPC*, *KCNN4*, *PIEZO1*, *RHAG*, *SLC2A1*, *SLC4A1*, *SPTA1*, and *SPTB*. See Method Description for additional details.

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for RBC membrane disorders.

#### Special Instructions

- [Informed Consent for Genetic Testing](#)
- [Metabolic Hematology Next-Generation Sequencing \(NGS\) Patient Information](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)
- [Hereditary Hemolytic Anemia Gene Panel and Subpanel Comparison](#)
- [Targeted Genes and Methodology Details for Red Blood Cell Membrane Disorders Gene Panel](#)

#### Highlights

This profile evaluates for hereditary (congenital) causes of red blood cell (RBC) membrane disorders. Symptoms should be long-standing or familial in nature.

#### Method Name

Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing

#### NY State Available

Yes

## Specimen

### Specimen Type

Varies

### Ordering Guidance

Multiple hematology gene panels are available. For more information see [Hereditary Hemolytic Anemia Gene Panel and Subpanel Comparison](#).

Targeted testing for familial variants (also called site-specific or known variants testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

### Additional Testing Requirements

This test is best interpreted in the context of protein studies and peripheral blood findings. Prior to sending this test, Coombs testing should be negative and consider evaluating a peripheral blood smear. This can be provided by ordering RBCME / Red Blood Cell Membrane Evaluation, Blood. Fill out the information sheet and indicate that a next-generation sequencing test was also ordered. Additionally, providing complete blood cell count data and clinical notes will allow more precise interpretation of results.

### Necessary Information

- [Metabolic Hematology Next-Generation Sequencing \(NGS\) Patient Information](#) is strongly recommended but not required. Testing may proceed without the patient information; however, it aids in providing a more thorough interpretation. Ordering healthcare professionals are strongly encouraged to complete the form and send it with the specimen
- If form not provided, include the following information with the test request: clinical diagnosis, pertinent clinical history (ie, complete blood cell count results and relevant clinical notes) and differentials based on any previous bone marrow studies, clinical or morphologic presentation.

### Specimen Required

**Specimen Type:** Whole blood

**Patient Preparation:** A previous bone marrow transplant from an allogeneic donor will interfere with testing. For information about testing patients who have received a bone marrow transplant, call 800-533-1710.

#### Container/Tube:

**Preferred:** Lavender top (EDTA)

**Acceptable:** Yellow top (ACD)

**Specimen Volume:** 3 mL

#### Collection Instructions:

- Invert several times to mix blood.
- Send whole blood specimen in original tube. **Do not aliquot.**

**Specimen Stability Information:** Ambient (preferred) 4 days/Refrigerated 4 days

**Additional Information:** To ensure minimum volume and concentration of DNA are met, the requested volume must be submitted. Testing may be canceled if DNA requirements are inadequate.

## Forms

1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:
  - [Informed Consent for Genetic Testing](#) (T576)
  - [Informed Consent for Genetic Testing \(Spanish\)](#) (T826)
2. [Metabolic Hematology Next-Generation Sequencing \(NGS\) Patient Information](#) (T816)
3. If not ordering electronically, complete, print, and send a [Benign Hematology Test Request](#) (T755) with the specimen.

## Specimen Minimum Volume

1 mL

## Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

## Clinical & Interpretive

### Clinical Information

Next-generation sequencing is a methodology that can interrogate large regions of genomic DNA in a single assay. The presence and pattern of gene variants can provide critical diagnostic, prognostic, and therapeutic information for managing physicians.

This panel aids in the diagnosis and genetic counseling of individuals with red blood cell (RBC) membrane disorders, including hereditary spherocytosis, hereditary elliptocytosis, hereditary pyropoikilocytosis, Southeast Asian ovalocytosis, hereditary stomatocytosis (both overhydrated and dehydrated/hereditary xerocytosis subtypes), and cryohydrocytosis.(1-5)

The functional red cell membrane is composed of a cholesterol and phospholipid bilayer anchored by integral proteins to an elastic cytoskeletal network. These interactions form the shape, deformability, and proper ion balance of the cell. Abnormalities in these moieties result in RBC membrane disorders. Hereditary spherocytosis is a common membrane disorder that can be present in all ethnic groups. It is usually associated with visible spherocytes on the peripheral blood smear and can be associated with variable clinical features of hemolysis ranging from mild to severe. Paradoxically, erythrocytosis can occur after splenectomy. Hereditary elliptocytosis (HE) is another fairly common and clinically variable disorder that can range from normal RBC indices, in the large majority of cases, to a minor subset of patients with moderate to severe anemia. Common hereditary elliptocytosis is characterized by the presence of elliptocytes on the peripheral blood smear and the absence of anemia. Variants associated with HE have been reported in widely variable ethnicities with greater prevalence in populations overlapping the malaria belt. Hereditary pyropoikilocytosis is now best classified as a severe form of hereditary elliptocytosis. It is uncommon and presents in early childhood as a severe hemolytic anemia. These disorders are associated with marked poikilocytosis on the peripheral blood smear.(1,2)

Hereditary stomatocytosis is an RBC membrane permeability disorder that can manifest as the more common dehydrated hereditary stomatocytosis (DHSt), also known as hereditary xerocytosis (HX), and the rarer overhydrated hereditary stomatocytosis (OHSt) subtypes. These disorders are important to confirm or exclude as splenectomy has been associated with an increased risk for serious venous thrombosis and thromboembolism events and is contraindicated in published guidelines.<sup>(5)</sup> DHSt/HX manifests variably as mild to compensated anemia to some cases with increased hemoglobin levels. Some patients are asymptomatic, others show hemolysis after even nontraumatic exercise sessions. Others display perinatal edema and susceptibility to iron overload. DHSt/HX is associated with pseudohyperkalemia, increased MCHC (mean corpuscular hemoglobin concentration), and decreased osmotic fragility due to relative dehydration of the red blood cell. OHSt is similarly associated with anemia of variably severity but is associated with increased osmotic fragility due to a relatively overhydrated steady state.

## Reference Values

An interpretive report will be provided.

## Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.<sup>(6)</sup> Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

## Cautions

Clinical Correlations:

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If testing was performed because of a clinically significant family history, it is often useful to first test an affected family member. Detection of a reportable variant in an affected family member would allow for more informative testing of at-risk individuals.

To discuss the availability of additional testing options, or for assistance in the interpretation of these results, contact the Mayo Clinic Laboratories genetic counselors at 800-533-1710.

Technical Limitations:

Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results may occur. The depth of coverage may be variable for some target regions; assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.

This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins) of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.

**Deletion/Duplication Analysis:**

This analysis targets single and multi-exon deletions/duplications; however, in some instances, single exon resolution cannot be achieved due to isolated reduction in sequence coverage or inherent genomic complexity. Balanced structural rearrangements (such as translocations and inversions) may not be detected.

Deletion/duplication events that extend past the genes included on the panel may occur. In these instances, genes included in the ordered test are provided on the report and interpreted, and genomic breakpoints are reported if they are confirmed. However, copy number variants for genes not listed in the Method Description are typically not reported or interpreted for haploinsufficiency/triplosensitivity. CMA CB / Chromosomal Microarray, Congenital, Blood; WES PR / Panel to Whole Exome Sequencing Reflex Test, Varies; or WGSDX / Whole Genome Sequencing for Hereditary Disorders, Varies is recommended for a full interpretation of deletions/duplications predicted to extend past the genes included on the panel.

This test is not designed to detect low levels of mosaicism or to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

For detailed information regarding gene-specific performance and technical limitations, see Method Description or contact a laboratory genetic counselor.

If the patient has had an allogeneic hematopoietic stem cell transplant or a recent blood transfusion, results may be inaccurate due to the presence of donor DNA. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.

**Reclassification of Variants:**

Currently, it is not standard practice for the laboratory to systematically review previously classified variants on a regular basis. The laboratory encourages healthcare professionals to contact the laboratory at any time to learn how the classification of a particular variant may have changed over time. Due to broadening genetic knowledge, it is possible that the laboratory may discover new information of relevance to the patient. Should that occur, the laboratory may issue an amended report.

**Variant Evaluation:**

Evaluation and categorization of variants are performed using published American College of Medical Genetics and Genomics and the Association for Molecular Pathology recommendations as a guideline.<sup>(6)</sup> Other gene-specific guidelines may also be considered. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance. Variants classified as benign or likely benign are not reported.

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and periodic updates to these tools may cause predictions to change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgment.

Rarely, incidental or secondary findings may implicate another predisposition or presence of active disease. These findings will be carefully reviewed to determine whether they will be reported.

## Clinical Reference

1. Gallagher PG. Abnormalities of the erythrocyte membrane. *Pediatr Clin North Am.* 2013;60(6):1349-1362. doi:10.1016/j.pcl.2013.09.001
2. Barcellini W, Bianchi P, Fermo E, et al. Hereditary red cell membrane defects: diagnostic and clinical aspects. *Blood Transfus.* 2011;9(3):274-277. doi:10.2450/2011.0086-10
3. Zarychanski R, Schulz VP, Houston BL, et al. Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis. *Blood.* 2012;120(9):1908-1915. doi:10.1182/blood-2012-04-422253
4. Andolfo I, Russo R, Gambale A, Iolascon A. Hereditary stomatocytosis: an underdiagnosed condition. *Am J Hematol.* 2018;93(1):107-121. doi:10.1002/ajh.24929
5. Iolascon A, Andolfo I, Barcellini W, et al. Recommendations regarding splenectomy in hereditary hemolytic anemias. *Haematologica.* 2017;102(8):1304-1313. doi:10.3324/haematol.2016.161166
6. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-424

## Performance

### Method Description

Next-generation sequencing (NGS) and/or Sanger sequencing are performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known disease-causing variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for deletions-insertions (delins) less than 40 base pairs (bp), above 95% for deletions up to 75 bp, and insertions up to 47 bp. NGS and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of deletions and duplications in the genes analyzed.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. (Unpublished Mayo method)

See [Targeted Genes and Methodology Details for Red Blood Cell Membrane Disorders Gene Panel](#) for details regarding the targeted genes analyzed for each test and specific gene regions not routinely covered.

Reference transcript numbers may be updated due to transcript re-versioning. Always refer to the final patient report for gene transcript information referenced at the time of testing. Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

Genes analyzed: *ABCB6, ANK1, EPB41, EPB42, GYPC, KCNN4, PIEZO1, RHAG, SLC2A1, SLC4A1, SPTA1, and SPTB*

**PDF Report**

Supplemental

**Day(s) Performed**

Varies

**Report Available**

28 to 42 days

**Specimen Retention Time**

Whole blood: 2 weeks (if available); Extracted DNA: 3 months

**Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

**Fees & Codes**
**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

81405

81479

81479 (if appropriate for government payers)

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
NMEM	RBC Membrane Sequencing, NGS	103738-1

Result ID	Test Result Name	Result LOINC® Value
619062	Test Description	62364-5
619063	Specimen	31208-2
619064	Source	31208-2
619065	Result Summary	50397-9
619066	Result	82939-0
619067	Interpretation	59465-5

## Test Definition: NMEM

Red Blood Cell Membrane Disorders Gene Panel, Next-Generation Sequencing, Varies

619068	Additional Results	82939-0
619069	Resources	99622-3
619070	Additional Information	48767-8
619071	Method	85069-3
619072	Genes Analyzed	82939-0
619073	Disclaimer	62364-5
619074	Released By	18771-6